e-learning
resources
Munich 2014
Tuesday, 09.09.2014
Pulmonary hypertension: improving treatment in PAH
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Anti-remodeling potencies of the soluble guanylate cyclase activator BAY 41-2272 in human lung fibroblasts
C. Lambers, M. Roth, E. Hofbauer, V. Petkov, L. H. Block (Vienna, Austria; Basel, Switzerland)
Source:
International Congress 2014 – Pulmonary hypertension: improving treatment in PAH
Session:
Pulmonary hypertension: improving treatment in PAH
Session type:
Oral Presentation
Number:
3423
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Lambers, M. Roth, E. Hofbauer, V. Petkov, L. H. Block (Vienna, Austria; Basel, Switzerland). Anti-remodeling potencies of the soluble guanylate cyclase activator BAY 41-2272 in human lung fibroblasts. Eur Respir J 2014; 44: Suppl. 58, 3423
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Treprostinil prodrugs for pulmonary arterial hypertension evaluated in cAMP profiling studies in live CHO-K1 cells
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Prevention of monocrotaline-induced pulmonary vascular and myocardial remodeling by the selective neutrophil elastase inhibitor BAY 85-8501
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Acid sphingomyelinase, a novel pathway for pulmonary vasoconstriction. Activation by apoptotic T cell microparticles and Fas ligand
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Anti-contractile and anti-proliferative responses in human pulmonary arterial smooth muscle cells induced by ACT-333679, the active metabolite of selexipag, a non-prostanoid selective prostacyclin receptor agonist
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Obligatory role of MEK/ERK/RSK90 in the mitogenic responses of human pulmonary artery smooth muscle cells
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Selective inhibition of neutrophil elastase by BAY 85-8501 improves exercise capacity and pulmonary hypertension in a porcine pancreatic elastase-induced emphysema model
Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH
Year: 2014
Nuclear factor-kappa B inhibition exerts anti-remodelling effects in pulmonary arterial smooth muscle cells
Source: International Congress 2014 – Pathobiology of pulmonary hypertension
Year: 2014
A soluble guanylate cyclase stimulator, BAY 41-8543, preserves pulmonary artery endothelial function in experimental pulmonary embolism
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
PKCalpha deficiency in mice is associated with pulmonary vascular hyperresponsiveness to thromboxane A
2
via increased TXA
2
receptor expression
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Nuclear IL-33 arguments ST2 receptor expression in pulmonary arterial endothelial cells: Implication in the pathogenesis and progression of pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Neuron-derived orphan receptor 1 mediated human pulmonary arterial smooth muscle cells proliferation via cyclin D1
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
M2 macrophages derived from patients with idiopathic pulmonary arterial hypertension are susceptible for apelin-mediated suppression of pro-inflammatory cytokines
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
MicroRNA-155 controls pulmonary artery fibroblast cell signalling and proliferation in a knockout mouse model: A role in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Role of NMDA receptors in vascular remodelling associated to pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Derivation and characterisation of endothelial cells from patients with chronic thromboembolic pulmonary hypertension
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
Modulation of symmetric dimethyarginine formation by apelin in human pulmonary endothelial cells
Source: International Congress 2015 – Translational research in respiratory care: new findings
Year: 2015
The role of anion exchanger on pulmonary vascular response to sustained alveolar hypoxia in the isolated perfused rabbit lung
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
ASK1 promotes maladaptive remodeling in a rodent model of pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
Oral delivery of transplastomic plant derived angiotensin converting enzyme2 - a novel approach for pulmonary hypertension therapeutics
Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH
Year: 2014
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept